Sakura Bio

Company Overview

Snapshot

Founded in October 2022, Sakura Bio operates with 1–10 employees. The company has raised $1.7M across one funding round from one investor. In May 2025, Sakura Bio secured Pre-Seed funding from VLX Ventures.

Business overview

Sakura Bio is a Health Tech & Life Sciences company focused on developing allogeneic cell therapy to combat cancer, particularly acute myeloid leukemia. The company's core technology involves creating super-activated killer cells, an allogeneic T-cell therapy derived from naïve PBMCs. Its lead product, Super Activated Killer T-cell (SAK-T), offers superior anti-tumor cytotoxic activity with a high safety profile, distinguishing it from other T-cell-based products like CAR-T by avoiding graft-versus-host disease and enabling off-the-shelf application. Sakura Bio targets the healthcare and laboratory markets within the Drugs Discovery & Development sector.

Company Intelligence Q&A

What is Sakura Bio's primary focus?

Sakura Bio is focused on developing an off-the-shelf, naïve PBMC-derived allogeneic T-cell therapy to fight cancer, specifically acute myeloid leukemia.

What is the company's lead product?

Sakura Bio's lead product is Super Activated Killer T-cell (SAK-T), a unique T-cell population designed for superior anti-tumor cytotoxic activity without toxicity to healthy tissue.

When was Sakura Bio founded?

Sakura Bio was founded in October 2022.

What is the key advantage of SAK-T cells?

SAK-T cells offer a high safety profile with no graft-versus-host disease, allowing them to be developed as an off-the-shelf T-cell product, unlike other T-cell-based therapies such as CAR-T.

What is Sakura Bio's total funding to date?

Sakura Bio has raised a total of $1.7 million across one funding round.